Table 1.
Baseline demographic and clinical characteristics of the patients.
| Parameter | JIA (n = 65) | Control (n = 31) | p Value |
|---|---|---|---|
| Median (Range) | Median (Range) | ||
| Age (years) | 11.0 (2.0–17.0) | 10.0 (2.0–18.0) | 0.065 |
| ESR (mm/h) | 13.0 (2.0–121) | 8.0 (2.0–30.0) | 0.14 |
| CRP (mg/dL) | 0.0 (0.0–7.5) | 0.0 (0.0–1.2) | 1.0 |
| Anti-pneumococcal vaccination | 10 (15.4%) | 12 (38.7%) | 0.018 |
| Anti-influenza vaccination | 7 (10.8%) | 3 (9.7%) | 1.0 |
| Contact with COVID-19 case | 3 (4.6%) | 6 (19.4%) | 0.054 |
| Disease activity | ND | ND | |
| JADAS 71 | 5.25 (0.0–38.0) | ||
| Active joint number | 1.0 (0.0–24.0) | ||
| PGA | 2.0 (0.0–7.0) | ||
| PhGA | 2.0 (0.0–8.0) | ||
| Treatment | ND | ND | |
| Conventional synthetic DMARDs | 60 (92,3%) | ||
| Methotrexate | 48 (73.9%) | ||
| Hydroxychloroquine | 5 (7.7%) | ||
| Sulfasalazine | 13 (20.0%) | ||
| GC | 14 (21.5) | ||
| Biological DMARDs | 33 (50.8%) | ||
| Adalimumab | 18 (54.6%) | ||
| Etanercept | 11 (33.3%) | ||
| Tocilizumab | 4 (12.1%) |
JIA, juvenile idiopathic arthritis; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; JADAS 71, juvenile arthritis disease activity score 71; PhGA, physician global assessment of disease activity; PGA, parent/patient assessment of overall well-being; ND, not determined, DMARDs, disease-modifying antirheumatic drugs; GC systemic glucocorticoids (orally, more than to 2 weeks, regardless of the dose).